Association of HDL cholesterol and triglycerides with mortality in patients with heart failure

Brazilian Journal of Medical and Biological Research

Volumn 42, Issue 5, 2009, Pages 420-425

  Freitas, H F G ^a   Barbosa, E A ^a   Rosa, F H F P ^a   Lima, A C P ^a   Mansur, A J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chagas' heart disease; HDL cholesterol; Heart failure; Prognosis; Triglycerides

Indexed keywords

CAPTOPRIL; CARVEDILOL; DIGOXIN; ENALAPRIL; FUROSEMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOMYOPATHY; CAUSAL ATTRIBUTION; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; FEMALE; HEART FAILURE; HUMAN; HYPERTENSIVE HEART DISEASE; ISCHEMIC CARDIOMYOPATHY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SURVIVAL RATE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 68249150838     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009000500004     Document Type: Article

References (21)

1. Rauchhaus M, Koloczek V, Volk H, Kemp M, Niebauer J, Francis DP, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 2000; 76: 125-133.
2. Sharma R, Anker SD. Immune and neurohormonal pathways in chronic heart failure. Congest Heart Fail 2002; 8: 23-8, 48.
3. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8: 216-224.
4. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-1940.
5. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018.
6. Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J 2006; 152: 1077-1083.
7. May HT, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Campbell BA, et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol 2006; 98: 653-658.
8. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356: 930-933.
9. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002; 85: 51-66.
10. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol 2005; 46: 1792-1798.
11. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995; 92: 3593-3612.
12. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-1446.
13. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 1980; 44: 672-673.
14. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841-842.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Cox DR. Regression models and life tables. J R Stat Soc B 1968; 30: 248-275.
17. Christ M, Klima T, Grimm W, Mueller HH, Maisch B. Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J 2006; 27: 691-699.
18. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-772.
19. Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. Int J Cardiol 2005; 102: 239-247.
20. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
21. Kontush A, Guerin M, Chapman MJ. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008; 5: 329-336.